Results 101 to 110 of about 11,885 (204)

Galantamine: a randomised, double-blind, dose-finding trial in patients with Alzheimer's disease

, 2001
Objectives: to investigate whether Galantamine significantly improves the core symptoms of Alzheimer's disease (AD).Background: galantamine is a reversible, competitive, selective inhibitor of acetylcholinesterase (AChE) that also allosterically ...
Murray, J., Wilkinson, D.
core   +1 more source

An open-label extension trail of galantamine in patients with probable vascular dementia and mixed dementia

, 2003
Background: Alzheimer's disease (AD) and vascular dementia (VaD) are the most common types of dementia worldwide. Galantamine, an acetylcholinesterase inhibitor and allosteric nicotinic modulator, has shown broad clinical benefits in patients with mild ...
Erkinjuntti, Timo, Bullock, Roger A., Kurz, Alexander, Small, Gary W., Lilienfeld, Sean, Damaraju, C.V.   +5 more
core   +1 more source

NMR Metabolomic Profiling of Differentiated SH-SY5Y Neuronal Cells: Amyloid-β Toxicity and Protective Effects of Galantamine and Lycorine

Cells
Alzheimer’s disease (AD) is a multifactorial neurodegenerative disorder characterized by metabolic dysregulation, oxidative stress, amyloid-β (Aβ) aggregation, metal dyshomeostasis, and mitochondrial dysfunction.
Arian Kola, Filippo Costanti, Jordan Kahfi, Abdul-Hamid Emwas, Mariusz Jaremko, Daniela Valensin   +5 more
doaj   +1 more source

Adjunctive galantamine, but not donepezil, enhances the antipsychotic-like effect of raclopride in rats

, 2020
Acetylcholine (ACh) esterase inhibitors like galantamine and donepezil have been tested as adjunct treatment in schizophrenia. Although ACh esterase inhibition might confer some antipsychotic activity, the role of allosteric potentiation of nicotinic ACh
Carina Sandbäck, Marie-Louise Wadenberg, Charlotte Wiker, Torgny H Svensson, Bjö Rn Schilström   +4 more
core  

A comparison of central and peripheral effect of galantamine.

, 2010
Galantamine is a reversible inhibitor of acety1cholinesterase (AchE). It is recommended for the treatment of rnild to moderate Alzheimer's dementia, vascular dementia and dementia with Lewy bodies.
Galusová, Petra
core   +1 more source

Galantamine versus risperidone for agitation in people with dementia : a randomized, twelve-week, single-center study

, 2014
AIMS: To examine the effects of galantamine and risperidone on agitation in patients with dementia.METHODS: A total of 100 patients with dementia and neuropsychiatric symptoms (mean age ± SD: 78.6 ± 7.5 years; 67% female) were included in this 12-week ...
Aarsland, Dag,, Bloniecki, Victor,, Tysen Bäckström, Ann Christine,, Lärksäter, Marie,, Freund-Levi, Yvonne,, Auestad, Bjørn,   +5 more
core   +1 more source

An open-label extension trial of galantamine in patients with probable vascular dementia and mixed dementia.

, 2003
BACKGROUND: Alzheimer's disease (AD) and vascular dementia (VaD) are the most common types of dementia worldwide. Galantamine, an acetylcholinesterase inhibitor and allosteric nicotinic modulator, has shown broad clinical benefits in patients with mild ...
Erkinjuntti, T;Kurz, A;Small, GW;Bullock, R;Lilienfeld, S;Damaraju, CV
core  

Galantamine: A Pharmacoeconomic Review of its Use in Alzheimer's Disease

Galantamine is one of several orally administered cholinesterase inhibitors that improve cognition in patients with mild to moderate Alzheimer's disease. Compared with placebo, galantamine 16 or 24 mg/day improved cognition and activities of daily living,
Greg L. Plosker, Katherine A. Lyseng-Williamson   +1 more
core  

Formulation and Evaluation of Galantamine Hydrobromide Extended Release Capsules [PDF]

, 2013
The present study was to develop extended release Galantamine capsules and these were compared with the Innovator product (Razadyne). The purpose of the present work was aimed at the following objectives.
Babuji, Kantu
core  

Acetylcholinesterase inhibitor therapy mitigates hypertension in lupus mice. [PDF]

Clin Sci (Lond)
Das-Earl P, Shimoura CG, Young-Stubbs CM, Chaudhari SK, Dinh VQ, Mathis KW.   +5 more
europepmc   +1 more source